公开(公告)号：US09174992B2

公开(公告)日：2015-11-03

申请号：US13780557

申请日：2013-02-28

Applicant: Amgen Inc.

Inventor： Jennifer R. Allen ,  Albert Amegadzie ,  Kristin L. Andrews ,  James Brown ,  Jian J. Chen ,  Ning Chen ,  Essa Hu Harrington ,  Qingyian Liu ,  Thomas T. Nguyen ,  Alexander J. Pickrell ,  Wenyuan Qian ,  Shannon Rumfelt ,  Robert M. Rzasa ,  Chester Chenguang Yuan ,  Wenge Zhong

IPC: C07D419/14 ,  C07D419/12 ,  C07D487/04 ,  C07D498/04 ,  C07D473/00 ,  C07D471/04 ,  C07D513/04 ,  C07D417/12 ,  C07D473/30 ,  C07D473/34 ,  C07D473/40 ,  C07D519/00

CPC classification number: C07D487/04 ,  C07D417/12 ,  C07D471/04 ,  C07D473/00 ,  C07D473/30 ,  C07D473/34 ,  C07D473/40 ,  C07D498/04 ,  C07D513/04 ,  C07D519/00

Abstract: Heterobicyclic compounds of Formula (I): or a pharmaceutically-acceptable salt, tautomer, or stereoisomer thereof, as defined in the specification, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, Huntington's Disease, and the like.

Abstract translation: 式（I）的异双环化合物：或其药学上可接受的盐，互变异构体或立体异构体，以及含有它们的组合物，以及制备这些化合物的方法。 本文还提供治疗通过抑制PDE10可治疗的疾病或疾病的方法，例如肥胖症，非胰岛素依赖性糖尿病，精神分裂症，双相情感障碍，强迫症，亨廷顿舞蹈病等。

公开(公告)号：US20130338138A1

公开(公告)日：2013-12-19

申请号：US13917699

申请日：2013-06-14

Applicant: AMGEN INC.

Inventor： Jennifer R. Allen ,  Jian J. Chen ,  Michael J. Frohn ,  Matthew R. Kaller ,  Qingyian Liu ,  Thomas T. Nguyen ,  Alexander J. Pickrell ,  Wenyuan Qian ,  Robert M. Rzasa ,  Wenge Zhong

IPC: C07D401/14 ,  C07D471/04 ,  A61K31/517 ,  A61K31/497 ,  A61K45/06

CPC classification number: C07D471/04 ,  A61K31/497 ,  A61K31/517 ,  A61K45/06 ,  C07D401/04 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14

Abstract: Azetidine and piperidine compounds of formula (I): as defined in the specification, compositions containing them, and processes for preparing such compounds and intermediates thereof. Provided herein also are methods of treating cognitive disorders or diseases treatable by inhibition of PDE10, such as Huntington's Disease, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.

Abstract translation: 式（I）的氮杂环丁烷和哌啶化合物：如说明书中所定义，含有它们的组合物，以及制备这些化合物的方法及其中间体。 本文还提供治疗认知障碍或通过抑制PDE10可治疗的疾病的方法，例如亨廷顿舞蹈病，精神分裂症，双相障碍，强迫症等。

公开(公告)号：US10947223B2

公开(公告)日：2021-03-16

申请号：US16466211

申请日：2017-12-13

Applicant: AMGEN INC.

Inventor： Jennifer R. Allen ,  Matthew P. Bourbeau ,  Ning Chen ,  Michael J. Frohn ,  Paul E. Harrington ,  Qingyian Liu ,  Corey Reeves

IPC: A61K31/535 ,  A61K31/536 ,  A61K31/537 ,  C07D265/08 ,  C07D265/12 ,  C07D265/30 ,  C07D413/10 ,  A61P25/28 ,  C07D413/14

Abstract: The present disclosure provides a class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: (insert Formula I structure) wherein variables W, X, Y, R2, R2′, R3, R4, R5, R6, and R7 of Formula I are defined herein. This disclosure also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to beta amyloid (Aβ) plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, and other central nervous system conditions.

公开(公告)号：US10889581B2

公开(公告)日：2021-01-12

申请号：US16466199

申请日：2017-12-13

Applicant: AMGEN INC.

Inventor： Jennifer R. Allen ,  Albert Amegadzie ,  Matthew P. Bourbeau ,  Jian J. Chen ,  Michael J. Frohn ,  Paul E. Harrington ,  Jonathan D. Low ,  Vu V. Ma ,  Thomas T. Nguyen ,  Alexander Pickrell ,  Corey Reeves

IPC: C07D471/14 ,  C07D417/14 ,  C07D417/10

Abstract: The present disclosure provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A, R1, R2, R2′, R3, R4, and R5 of Formula I are defined herein. This disclosure also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to Aβ plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, and other central nervous system conditions.

公开(公告)号：US20160280703A1

公开(公告)日：2016-09-29

申请号：US14579733

申请日：2014-12-22

Applicant: Amgen Inc.

Inventor： Jennifer R. Allen ,  Michael J. Frohn ,  Paul E. Harrington ,  Essa Hu Harrington ,  Alexander J. Pickrell

IPC: C07D417/14 ,  C07D413/14 ,  C07D471/04 ,  C07D417/12 ,  C07D487/04 ,  C07D405/14 ,  C07D401/14

CPC classification number: C07D417/14 ,  C07D401/14 ,  C07D403/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/12 ,  C07D471/04 ,  C07D487/04

Abstract: Heteroaryloxycarbocyclyl compounds, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, Huntington's Disease, bipolar disorder, obsessive-compulsive disorder, and the like.

Abstract translation: 杂芳氧基碳环化合物和含有它们的组合物，以及制备这些化合物的方法。 本文还提供治疗通过抑制PDE10可治疗的疾病或疾病的方法，例如肥胖症，非胰岛素依赖性糖尿病，精神分裂症，亨廷顿舞蹈病，双相情感障碍，强迫症等。

公开(公告)号：US09376450B2

公开(公告)日：2016-06-28

申请号：US13892196

申请日：2013-05-10

Applicant: Amgen Inc.

Inventor： Jennifer R. Allen ,  Daniel B. Horne ,  Essa Hu Harrington ,  Matthew R. Kaller ,  Holger Monenschein ,  Thomas T. Nguyen ,  Andreas Reichelt ,  Robert M. Rzasa

IPC: C07D491/107 ,  C07D413/14 ,  C07D403/04 ,  C07D403/14 ,  C07D487/04 ,  C07D487/10 ,  C07D401/04 ,  C07D401/06 ,  C07D405/14 ,  C07D405/04 ,  C07D401/14 ,  C07D417/14 ,  C07D471/04 ,  C07D471/08 ,  C07D409/14

CPC classification number: C07D491/107 ,  C07D401/04 ,  C07D401/06 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D405/04 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D471/08 ,  C07D487/04 ,  C07D487/10

Abstract: Heteroaryloxyheterocyclyl compounds, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, Huntington's Disease, bipolar disorder, obsessive-compulsive disorder, and the like.

公开(公告)号：US09303028B2

公开(公告)日：2016-04-05

申请号：US14170146

申请日：2014-01-31

Applicant: AMGEN INC.

Inventor： Jennifer R. Allen ,  Jian J. Chen ,  Michael J. Frohn ,  Matthew R. Kaller ,  Qingyian Liu ,  Thomas T. Nguyen ,  Alexander J. Pickrell ,  Wenyuan Qian ,  Robert M. Rzasa ,  Wenge Zhong

IPC: A61K31/497 ,  A61K31/517 ,  C07D401/14 ,  C07D403/14 ,  C07D471/04 ,  A61K45/06

CPC classification number: C07D471/04 ,  A61K31/497 ,  A61K31/517 ,  A61K45/06 ,  C07D401/04 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14

Abstract: Azetidine and piperidine compounds of formula (I): as defined in the specification, compositions containing them, and processes for preparing such compounds and intermediates thereof. Provided herein also are methods of treating cognitive disorders or diseases treatable by inhibition of PDE10, such as Huntington's Disease, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.

Abstract translation: 式（I）的氮杂环丁烷和哌啶化合物：如说明书中所定义，含有它们的组合物，以及制备这些化合物的方法及其中间体。 本文还提供治疗认知障碍或通过抑制PDE10可治疗的疾病的方法，例如亨廷顿舞蹈病，精神分裂症，双相障碍，强迫症等。

公开(公告)号：US20130225552A1

公开(公告)日：2013-08-29

申请号：US13780557

申请日：2013-02-28

Applicant: Amgen Inc.

Inventor： Jennifer R. Allen ,  Albert Amegadzie ,  Kristin L. Andrews ,  James Brown ,  Jian J. Chen ,  Ning Chen ,  Essa Hu Harrington ,  Qingyian Liu ,  Thomas T. Nguyen ,  Alexander J. Pickrell ,  Wenyuan Qian ,  Shannon Rumfelt ,  Robert M. Rzasa ,  Chester Chenguang Yuan ,  Wenge Zhong

IPC: C07D487/04 ,  C07D513/04 ,  C07D471/04 ,  C07D498/04 ,  C07D473/00

CPC classification number: C07D487/04 ,  C07D417/12 ,  C07D471/04 ,  C07D473/00 ,  C07D473/30 ,  C07D473/34 ,  C07D473/40 ,  C07D498/04 ,  C07D513/04 ,  C07D519/00

Abstract: Heterobicyclic compounds of Formula (I): or a pharmaceutically-acceptable salt, tautomer, or stereoisomer thereof, as defined in the specification, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, Huntington's Disease, and the like.

Abstract translation: 式（I）的异双环化合物：或其药学上可接受的盐，互变异构体或立体异构体，以及含有它们的组合物，以及制备这些化合物的方法。 本文还提供治疗通过抑制PDE10可治疗的疾病或疾病的方法，例如肥胖症，非胰岛素依赖性糖尿病，精神分裂症，双相情感障碍，强迫症，亨廷顿舞蹈病等。

公开(公告)号：US10246429B2

公开(公告)日：2019-04-02

申请号：US15749895

申请日：2016-08-04

Applicant: AMGEN INC.

Inventor： Jennifer R. Allen ,  Albert Amegadzie ,  Matthew P. Bourbeau ,  James A. Brown ,  Ning Chen ,  Michael J. Frohn ,  Longbin Liu ,  Qingyian Liu ,  Liping H. Pettus ,  Wenyuan Qian ,  Corey M. Reeves ,  Aaron C. Siegmund

IPC: C07D417/10 ,  C07D279/08 ,  C07D417/14 ,  C07D471/04 ,  C07D491/056 ,  A61P25/28 ,  A61P25/00 ,  A61P25/16 ,  C07D491/08 ,  C07D491/107 ,  C07D498/10 ,  C07F7/08

Abstract: The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A4, A5, A6, A7, and each of Ra, Rb, R1, R2, R3, R8 R9 and R10 of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to Aβ plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions.

公开(公告)号：US09309263B2

公开(公告)日：2016-04-12

申请号：US14166012

申请日：2014-01-28

Applicant: AMGEN INC.

Inventor： Ryan White ,  Jennifer R. Allen ,  Oleg Epstein ,  Fang-Tsao Hong ,  Zihao Hua ,  Jason Brooks Human ,  Patricia Lopez ,  Philip R. Olivieri ,  Karina Romero ,  Laurie Schenkel ,  John Stellwagen ,  Nuria A. Tamayo ,  Xiao Mei Zheng

IPC: C07D417/10 ,  C07D417/14 ,  C07D513/04 ,  C07D513/14 ,  C07D417/12 ,  C07D471/04 ,  C07D487/04 ,  C07D513/10 ,  C07D513/20 ,  C07D519/00

CPC classification number: C07D513/04 ,  C07D417/12 ,  C07D471/04 ,  C07D487/04 ,  C07D513/10 ,  C07D513/14 ,  C07D513/20 ,  C07D519/00

Abstract: The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A5, A6, A8, R1, R2, R3, R7, X, Y, n and o of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and corresponding uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formula II and sub-formula embodiments thereof, compounds of Formula III, intermediates and processes and methods useful for the preparation of compounds of Formulas I-III, and sub-Formulas thereof.

Abstract translation: 本发明提供了一类可用于调节β-分泌酶（BACE）活性的化合物。 化合物具有通式I：其中式I的变量A5，A6，A8，R1，R2，R3，R7，X，Y，n和o独立地在本文中定义。 本发明还提供包含该化合物的药物组合物，以及用于治疗由BACE的生物学活性产生的A-β斑块形成和沉积相关的病症和/或病症的化合物和组合物的相应用途。 这种BACE介导的疾病包括例如阿尔茨海默病，认知缺陷，认知障碍，精神分裂症和其他中枢神经系统疾病。 本发明还提供式II化合物及其次级实施方案，式III化合物，可用于制备式I-III化合物的中间体和方法和方法及其分式。